Mr. Brooks leads a team responsible for optimizing liquidity and use of capital resources, safeguarding Regenerons cash and investment portfolio, corporate risk management and maintaining strong relationships with financial institutions, insurance providers and rating agencies. In addition, he was a former director of Laboratory Corporation of America Holdings, Campus Crest Communities, Inc., CRISPR Therapeutics AG, and McKesson Corporation. Scribe Therapeutics - Alameda Mr. OLeary received his B.S. This information is according to proxy statements . Executive Vice President, Research and Development. CA. at Saint Johns University. Based on 12 salaries posted anonymously by AstraZeneca Vice President Finance employees in Seaham, England. Robert Vitti, MD Vice President, Clinical Sciences Ophthalmology Alyson Berliner, MD, PhD Executive Director, Ophthalmology October 11, 2019 Robert (Bob) Vitti and Alyson Berliner sit down to discuss their motivations for studying diabetic retinopathy (DR) and how their job was to shift the mindset around the disease. Gerald Underwood joined Regeneron in 1995 and serves as senior vice president, technical operations for the global industrial operations & product supply organization. Robert E. Landry joined Regeneron in 2013 and serves as executive vice president, finance and chief financial officer. Board of Directors in REGENERON PHARMACEUTICALS, INC. In 2020, Ms. Bermingham stepped forward to also serve as the companys interim head of diversity, equity and inclusion (DE&I). Brown and Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985 and the U.S. National Medal of Science in 1988. Neil Stahl, Ph.D., joined Regeneron in 1991 and has served as executive vice president, research and development since January 2015. Si vous continuez voir ce From 2008 to 2015, Dr. Herman was one of only three pharmaceutical industry members on the Executive Committee of the Biomarkers Consortium, a program within the Foundation for the National Institutes of Health. After a pair of monumental payouts in 2020, the compensation packages for Regeneron's top executives have come back down to Earth. Dr. Goldstein is a member of the National Academy of Sciences, the National Academy of Medicine and the Royal Society of London. The estimated base pay is $208,591 per year. ein Mensch und keine Maschine sind. David Simon has been with Regeneron since 1998 and is the senior vice president of industrial operations and product supply (IOPS) finance & business operations. Before joining Regeneron, Christina served as vice president, global finance communication at Johnson & Johnson (J&J). It is especially meaningful that this award is based in part on the quality and consistency of employee reviews on Glassdoor. With over 30 years global experience, Mr. McCowan leads the companys IT organization and is responsible for global IT strategy supporting research, commercial, cyber security and enterprise operations. Prior to joining Regeneron, Ms. Lozner served as chief compliance officer and special counsel at Rafael Holdings, where she was responsible for building a compliance program for a start-up biotechnology company. Merck VA. He also is a member of the boards of trustees of The Rockefeller University and the Howard Hughes Medical Institute. Dr. Soltys received his B.S. Senior Vice President, Translational and Clinical Sciences, Oncology. L. Andres Sirulnik, M.D., Ph.D. joined Regeneron in 2020 and serves as senior vice president, translational & clinical sciences, hematology, leading strategic program direction and clinical sciences work for our early- and late-stage oncologic hematology and late-stage non-oncology hematology portfolios. The estimated total pay for a Vice President at Regeneron is $420,792 per year. Based on 1 salaries posted anonymously by IPSEN Vice President Human Resources employees in Wherstead, England. Regeneron employees rate the overall compensation and benefits package 4.2/5 stars. Takeda Abbvie in biology from the University of Science and Technology of China and his Ph.D. in cell biology from the University of Washington. in marketing at Auburn University and his MBA at New York University. in biology from the University of Massachusetts. Prior to Merus N.V., he spent a decade at Novartis in various roles of increasing responsibility, ultimately overseeing the clinical strategy for their immuno-oncology portfolio. Dr. Schleifer is a licensed physician and is certified in neurology by the American Board of Psychiatry and Neurology. REGENERON PHARMACEUTICALS, INC. annual reports of executive compensation and pay are most commonly found in the Def 14a documents. AstraZeneca. #GlassdoorBPTW, We are excited to share that for the second year in a row, BioSpace has named us a Best Place to Work. He previously held roles on the tax teams at Arthur Anderson, Ernst & Young, and Diageo, and he currently serves as secretary and member of the board of trustees at Intensive Therapeutics, a 501c3 non-profit organization that provides therapy services to children with special needs. Based on 12 salaries posted anonymously by AstraZeneca Vice President Finance employees in Burton Latimer, England. The estimated salary at Regeneron ranges from approximately $51,662 per year for Human Resources Specialist to $226,077 per year for Director. As Executive Vice President and General Manager, Industrial Operations and Product Supply at REGENERON PHARMACEUTICALS, INC., Daniel Van Plew made $8,978,600 in total compensation. from New York University. in biotechnology from Dublin City University, Ireland and his MBA from the Williams College of Business at Xavier University in Cincinnati, Ohio. Prior to that she was chief diversity officer for Dow Jones, including its flagship brand, The Wall Street Journal. VA. Drs. The "Most Likely Range" represents values that exist within the 25th and 75th percentile of all pay data available for this role. $0. Mr. Fenimore holds an M.A. CA. .css-r1m4lw{background-color:#20262e;border-radius:50%;}.css-r1m4lw > svg > path{fill:#fff;}Add your salary. Professor, Departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience, Baylor College; Director, Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital. President, Chief Executive Officer and Chairman of the Board, Cerevel Therapeutics Holdings, Inc. Dr. Coles has been a director of the company since 2017. Senior Vice President, Immuno-Oncology and Head of Bispecifics. from Siena College and his MBA from State University of New York at Albany. Boyce F. Martin, Jr., Chief Judge Emeritus, U.S. Court of Appeals for the Sixth Circuit. Mastercard - Arlington From 2006 to 2007, he served as executive vice president, R&D and technical operations of Crucell Holland B.V., a global biopharmaceutical company. Prior to joining Regeneron, Mr. Landry served as senior vice president and treasurer of Pfizer Inc. Mr. Landry also held a variety of U.S. and international financial and general management positions at Wyeth Pharmaceuticals, Pfizer and PricewaterhouseCoopers LLP, including at Wyeth's Australian and New Zealand affiliates. She currently serves as senior vice president, development operations and portfolio management and is responsible for clinical trial strategy and execution, along with overseeing our development shared services functions. Prior to joining Regeneron, Dr. Zambrowicz held roles of increasing responsibility from 1996 to 2015 at Lexicon Pharmaceuticals, Inc., ultimately serving as executive vice president and chief scientific officer. Executive Vice President, Human Resources. from Boston University School of Law. In her role, Dr. Morton has led the discovery and development of a highly innovative and diverse portfolio across disease areas. Prior to that, Dr. Herman completed his residency and postdoctoral training at University of California, San Francisco and was an assistant professor there before joining industry. Prior to Regeneron, Mr. ONeal held roles at Axovant, Amgen and Express Scripts. Dr. DiCioccio earned an B.S. Ajude-nos a manter o Glassdoor seguro confirmando que voc uma pessoa de Also, proxies must disclose specific detailed information regarding the pay practices for certain executives. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. Regeneron employees attributed a compensation and benefits rating of 4.2/5 stars to their company. She earned a B.S. Dr. Yancopoulos, together with key members of his team, is a principal inventor and/or developer of the nine FDA-approved drugs Regeneron has developed: EYLEA (aflibercept) Injection, Praluent (alirocumab), Dupixent (dupilumab), Kevzara (sarilumab), Libtayo (cemiplimab), EvkeezaTM (evinacumab-dgnb), Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn), ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST (rilonacept) Injection for Subcutaneous Use, as well as Regeneron's foundation technologies, including the TRAP technology, VelociGene and VelocImmune. Lamentamos pelo inconveniente. Senior Vice President, Associate General Counsel. from the University at Albany and is a graduate of GEs Financial Services Leadership program. Gonzalo Merino, Ph.D., J.D., joined Regeneron in 2013 and now serves as senior vice president and chief intellectual property counsel. The pharmacometric functions are also responsible for the associated documentation needed to support clinical protocols, as well as the nonclinical PK and clinical pharmacology summaries for the global regulatory filings. Regeneron employees attributed a compensation and benefits rating of 4.2/5 stars to their company. Under Dr. Thompsons leadership, MSK physicians pioneered the use of novel immunotherapies such as checkpoint inhibitors and CAR-T cell therapies, as well as elevated the role of tumor sequencing in cancer care selection. The charts on this page feature a breakdown of the total annual pay for the top executives at REGENERON PHARMACEUTICALS, INC. as reported in their proxy statements. Dr. Thompson has been a director of the company since 2022. Prior to joining Regeneron, Dr. Lowy was at Medarex for eight years. She oversees global HR systems and processes and is expanding HR operations to support employees in a growing number of countries outside the U.S. Prior to joining Fisher, Ms. Poon was vice chair, worldwide chair of pharmaceuticals, member of the executive committee and director at Johnson & Johnson. The total cash compensation, which includes bonus, and annual incentives, can vary anywhere from $271,190 to $333,590 with the average total cash compensation of $295,590. Salary information comes from 1 data point collected directly from employees, users, and past and present job advertisements on Indeed in the past 24 months. She previously led communication for the cardiovascular & metabolism therapeutic area and global commercial strategy organization at Janssen, J&Js pharmaceutical division. In addition to a robust portfolio of antibody therapeutics, she has been a company leader in the application of novel nucleotide and gene therapies. Collectively, through integration of pharmacology with modeling and other quantitative methods, the functions within pharmacometrics play a central role in dose selection from first-in-human studies through global market applications as well as post-approval activities. VA. Job TitleVice President, Talent and LearningOverviewAccountable for developing and delivering andmember of the Global Talent and OE Leadership TeamAll About You Experience in HR Business City of Virginia Beach - Virginia Beach Dr. Zoghbi is the director of the Jan and Dan Duncan Neurological Research Institute at Texas Childrens Hospital, and is a Howard Hughes Medical Institute investigator. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings. Dr. Zambrowicz received his B.S. Senior Vice President, Global Medical Affairs. Before joining Regeneron, Mr. Underwood worked at Fluor Daniel, the Jacobs Engineering Group and Day Laboratories. Takeda Of this total $724,500 was received as a salary, $819,410 was received as a bonus, $3,347,323 was received in stock options, $2,231,397 was awarded as stock and $24,200 came from other types of compensation. The base salary for Vice President of Laboratory in companies like REGENERON PHARMACEUTICALS, INC. range from $240,390 to $292,490 with the average base salary of $262,090. J&J He earned his B.S. Prior to this role, he was senior vice president, late stage clinical development and medical affairs. $2.8M. Carver earned his B.S. Regeneron is an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion or belief (or lack thereof), sex,. Senior Vice President, Commercial Scale Manufacturing and Manufacturing Technology. Before this, Dr. Reinertsen served as the vice president of corporate development at Vertex Pharmaceuticals. Melissa Lozner, J.D., joined Regeneron in 2022 and serves and as senior vice president, chief compliance officer. Overall Benefits Rating.css-11cfy92{color:#0caa41 !important;}.css-11cfy92{color:#0caa41 !important;}4.1, Matches half of your contribution up to 5% (of gross pay) on 10%. Hanne Bak, Ph.D., joined Regeneron in 2004 and serves as senior vice president, preclinical manufacturing and process development (PMPD). He has been a professor of molecular genetics and internal medicine and the chair of the Department of Molecular Genetics at the University of Texas Southwestern Medical Center at Dallas since 1977. How accurate is this most likely Total Pay range (base + additional) of $329K-$554K/yr? Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. in chemistry from Penn State University and his MBA from Michigan State University. He received post graduate clinical training in OBGYN and gynecologic oncology at the University of Cambridge and Duke University Medical Center. , During her tenure, Dr. Morton has established cardiovascular, renal and fibrosis research at Regeneron. from Harvard University and her J.D. Senior Vice President, Corporate Communications and Citizenship. Prior to joining Regeneron, Ms. Ravetti spent 10 years at Pfizer in various positions of increasing responsibility, and she was previously an Associate at the law firm of Sullivan and Cromwell. envie um e-mail para Dr. Murphy is a co-inventor of several of Regeneron's key technologies, VelociGene and VelocImmune, and continues to lead several technology centers and therapeutic focus areas.
Keosha Ferguson Dc,
Articles R
